Nyxoah S.A. (NYXH)
NASDAQ: NYXH · IEX Real-Time Price · USD
9.10
-0.13 (-1.41%)
At close: Jul 19, 2024, 4:00 PM
9.27
+0.17 (1.87%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions.
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah S.A.
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 147 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-saint-guibert, C9 1435 Belgium | |
| Phone | 3210222355 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 0001857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| Loic Moreau | Chief Financial Officer |
| Bruno Onkelinx | Chief Technology Officer |
| Mikaela Kirkwood | Corporate Communication and Investor Relations Manager |
| An Moonen | General Counsel |
| Remi Renard | Vice President of Market and Market Access |
| Inge Vanwittenbergh | Global Human Resource Director |
| David M. DeMartino | Chief Strategy Officer |
| Jeyakumar Subbaroyan | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2024 | 6-K | Report of foreign issuer |
| Jul 5, 2024 | 6-K | Report of foreign issuer |
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jul 1, 2024 | 6-K | Report of foreign issuer |
| Jun 3, 2024 | 6-K | Report of foreign issuer |
| May 31, 2024 | 6-K | Report of foreign issuer |
| May 30, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 424B5 | Filing |